ANNE GEARY: Open Payments
NPI 1427434182 · INDIANAPOLIS, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$658 in 28 payments from 8 companies in 2025. Trend: 2023 $279 · 2024 $273 · 2025 $658
Food & beverage: $658
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 4 | $276 |
| Madrigal Pharmaceuticals | 15 | $163 |
| ABBVIE INC. | 3 | $87 |
| GENZYME CORPORATION | 1 | $39 |
| Ardelyx, Inc. | 2 | $36 |
| PFIZER INC. | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Celltrion USA Inc. | 1 | $18 |
Products named: TREMFYA, REZDIFFRA, RINVOQ, DUPIXENT, IBSRELA, SKYRIZI, XELJANZ, ENTYVIO.
Industry payments across IN — which companies pay providers there.
